Michael Vi / Shutterstock.com
Roche’s subsidiary Genentech has asked a Delaware court to block two of Novartis’ units from selling a generic version of the blockbuster lung-disease drug Esbriet (pirfenidone).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Roche, Genentech, Intermune, Novartis, Sandoz, Lek Pharmaceuticals, generics, ANDA, Esbriet, injunction